doi:10.1097/01.jcp.0000186738.84276.

9f [PubMed 16282852]

130. Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. J Am Geriatr Soc.
1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x [PubMed 3819263]

131. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J
Psychiatry. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347 [PubMed 22193526]

132. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41. doi:10.1056/NEJM199601043340109 [PubMed 7494570]
133. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the
treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872.
doi:10.1176/appi.ajp.2020.177901 [PubMed 32867516]

134. King DJ, Wager E. Haematological safety of antipsychotic drugs. J Psychopharmacol. 1998;12(3):283-288.
doi:10.1177/026988119801200309 [PubMed 10958256]

135. Klein LR, Driver BE, Miner JR, et al. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating
acute agitation in the emergency department. Ann Emerg Med. 2018;72(4):374-385. doi:
10.1016/j.annemergmed.2018.04.027. [PubMed 29885904]

136. Kliegman RM, Stanton BF, St. Geme Ill JW, Schor NF, Behrman RE, eds. Nelson Textbook of Pediatrics. 19th ed.
Philadelphia, PA: Elsevier Saunders; 2011.

137. Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier;
2020.

138. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. Hum Psychopharmacol.
2003;18(4):301-309. doi:10.1002/hup.483 [PubMed 12766935]

139. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The
Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr
Bull. 2010;36(1):94-103. doi:10.1093/schbul/sbp130 [PubMed 19955388]

140. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;73(6):435-456. [PubMed
10628896]

141. Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. Ann Pharmacother.
2005;39(11):1940-1942. [PubMed 16174785]

142. La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic
drugs: a critical review part II: antipsychotics. Pharmacopsychiatry. 2013;46(6):201-208. doi:10.1055/s-0033-
1347177 [PubMed 23737244]

143. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic
outcomes. J Clin Psychiatry. 2007;68(suppl 6):10-13. [PubMed 17650054]

144. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk
associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J
Geriatr Psychiatry. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007 [PubMed 24016844]

145. Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology;
Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy
 and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. doi:10.1111/acps.12479 [PubMed 26344706]

146. Lauriello J, Campbell AR. Pharmacotherapy for schizophrenia: long-acting injectable antipsychotic drugs. Post TW,
ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 7, 2020.

147. Lee AY. A case of leukocytoclastic vasculitis associated with haloperidol. Clin Exp Dermatol. 1999;24(5):430.
doi:10.1046/j.1365-2230.1999.00523.x [PubMed 10564343]

148. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice
Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry.
2004;161(2)(suppl):1-56. [PubMed 15000267]

149. Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. Am J
Psychiatry. 1979;136(8):1061-1064. [PubMed 380367]

150. Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, García M, Aguirre C. Antipsychotics and seizures:
higher risk with atypicals? Seizure. 2013;22(2):141-143. doi:10.1016/j.seizure.2012.10.009 [PubMed 23146619]

151. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Schizophr Bull. 2010;36(3):624-632. doi:10.1093/schbul/sbn120 [PubMed 18849294]

152. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14(2):85-93. [PubMed 18391612]
153. MacDonald K, Wilson M, Minassian A, et al. A naturalistic study of intramuscular haloperidol versus intramuscular
olanzapine for the management of acute agitation. J Clin Psychopharmacol. 2012;32(3):317-322. [PubMed
22544013]

154. Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report
and literature review. Pharmacopsychiatry. 2004;37(3):134-138. [PubMed 15138897]

155. Magliozzi JR, Gillespie H, Lombrozo L, Hollister LE. Mood alteration following oral and intravenous haloperidol
and relationship to drug concentration in normal subjects. J Clin Pharmacology. 1985;25(4):285-290. [PubMed
4008674]

156. Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of
delirium: a double-blind, randomized, controlled trial. Drug Des Devel Ther. 2013;7:657-667. doi:
10.2147/DDDT.S45575. [PubMed 23926422]

157. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry.
2004;161(8):1334-1349. [PubMed 15285957]

158. Marsh SJ, Dolson GM. Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy. Ren Fail.
1995;17(4):475-478. doi:10.3109/08860229509037611 [PubMed 7569118]

159. Marshall J, Herzig SJ, Howell MD, et al. Antipsychotic utilization in the intensive care unit and in transitions of care.
J Crit Care. 2016;33:119-124. doi: 10.1016/j.jcrc.2015.12.017. [PubMed 26818629]

160. Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. South Med J. 2002;95(8):799-802.
[PubMed 12190212]

161. Masiran R. Persistent oromandibular dystonia and angioedema secondary to haloperidol. BMJ Case Rep.
2017;2017:bcr2017220817. Published Oct 4, 2017. doi:10.1136/bcr-2017-220817 [PubMed 28978587]
162. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with
dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018
[PubMed 25786075]

163. McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and
treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107-
125. [PubMed 17195735]

164. McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues
(CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am
Acad Child Adolesc Psychiatry. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008 [PubMed 23972700]

165. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex
oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry. 1996;57(4):142-
146. [PubMed 8601548]

166. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry.
2006;67(suppl 5):15-18. [PubMed 16822092]

167. McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for
maintenance treatment of schizophrenia: a randomized clinical trial [published correction appears in JAMA.
2014;312(14):1473.] JAMA. 2014;311(19):1978-1987. [PubMed 24846035]

168. McVoy M, Findling RL, eds. Clinical Manual of Child and Adolescent Psychopharmacology. 3rd ed. Amer
Psychiatric Pub; 2017.

169. Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. Medications and Myasthenia Gravis (a Reference for Health Care
Professionals). Indiana University School of Medicine's Department of Neurology; 2012.

170. Mehta D, Mehta S, Petit J, Shriner W. Cardiac arrhythmia and haloperidol. Am J Psychiatry. 1979;136(11):1468-
1469. doi:10.1176/ajp.136.11.1468 [PubMed 91324]

171. Mercadante S. Bowel obstruction in home-care cancer patients: 4 years experience. Support Care Cancer.
1995;3(3):190-193. [PubMed 7544674]

172. Mercadante S. Palliative care of bowel obstruction in cancer patients. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed May 5, 2020.

173. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous
haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-E16. [PubMed
20394022]

174. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr
Pharmacol Ther. 2020;25(3):175-191. [PubMed 32265601]

175. Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with
schizophrenia, psychosis or bipolar disorder. Ther Adv Psychopharmacol. Published online July 6, 2020.
doi:10.1177/2045125320937910 [PubMed 32670542]

176. Moore GM, Pfaff JA. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed.
UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 7, 2020.
177. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients
maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Arch Gen Psychiatry.
1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007 [PubMed 8102845]

178. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622.
[PubMed 20187598]

179. Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP)
Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and
adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1341-1359. [PubMed 24290467]

180. Muzyk AJ, Cvelich RG, Kincaid BR, Preud'homme XA. Angioedema occurring in patient prescribed iloperidone and
haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes. J Neuropsychiatry Clin
Neurosci. 2012;24(2):E40-E41. doi:10.1176/appi.neuropsych.11040094 [PubMed 22772698]

181. National Collaborating Centre for Mental Health; National Institute for Health and Care Excellence. Violence and
aggression: short-term management in mental health, health and community settings: updated edition. London,
UK: British Psychological Society; 2015. https://www.nice.org.uk/guidance/ng10/resources/violence-and-
aggression-shortterm-management-in-mental-health-health-and-community-settings-1837264712389. Accessed
August 14, 2015. [PubMed 26180871]

182. National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health.
Psychosis and schizophrenia in children and young people: recognition and management. 2013. Available at
https://www.nice.org.uk/guidance/cg155. [PubMed 26065063]

183. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature
review. CNS Drugs. 2005;19 Suppl 1:1-93. doi:10.2165/00023210-200519001-00001 [PubMed 15998156]

184. Newport DJ, Calamaras MR, DeVane CL, et al, “Atypical Antipsychotic Administration During Late Pregnancy:
Placental Passage and Obstetrical Outcomes,” Am J Psychiatry, 2007, 164(8):1214-20. [PubMed 17671284]

185. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-
control study. Can J Psychiatry. 2012;57(8):512-518. doi:10.1177/070674371205700810 [PubMed 22854034]

186. Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double-blind, randomized trial of midazolam versus
haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med.
2004;11(7):744-749. [PubMed 15231461]

187. Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced
sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex
Marital Ther. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883 [PubMed 22533871]

188. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother. 1999;33(10):1046-
1050. doi:10.1345/aph.19017 [PubMed 10534216]

189. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with
antipsychotic medications. Am J Psychiatry. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821 [PubMed
17012695]

190. O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. Ann Pharmacother. 2003;37(11):1675-
1684. doi:10.1345/aph.1D056 [PubMed 14565800]
191. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid
tranquillisation). Cochrane Database Syst Rev. 2017;7:CD009377. doi: 10.1002/14651858.CD009377.pub3.
[PubMed 28758203]

192. Pappadopulos E, Rosato NS, Correll CU, et al. Experts' recommendations for treating maladaptive aggression in
youth. J Child Adolesc Psychopharmacol. 2011;21(6):505-515. doi:10.1089/cap.2010.0128 [PubMed 22196314]

193. Park Y, Bateman BT, Kim DH, et al. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death
in patients with acute myocardial infarction: cohort study. BMJ. 2018;360:k1218. doi:10.1136/bmj.k1218 [PubMed
29592958]

194. Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients
taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol. 2019;19(1):174. Published 2019 Jul
20. doi:10.1186/s12883-019-1385-4 [PubMed 31325958]

195. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv.
1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163 [PubMed 9735957]

196. Perera MA, Yogaratnam J. De Novo delayed onset hypothermia secondary to therapeutic doses of risperidone in
bipolar affective disorder. Ther Adv Psychopharmacol. 2014;4(2):70-74. doi:10.1177/2045125313507740 [PubMed
24688758]

197. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf.
2002;25(2):91-110. doi:10.2165/00002018-200225020-00004 [PubMed 11888352]

198. Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed October 29, 2020.

199. Pringsheim T, Okun MS, Müller-Vahl K, et al; Guideline Development, Dissemination, and Implementation
Subcommittee of the American Academy of Neurology (AAN). Practice guideline recommendations summary:
Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896-906.
[PubMed 31061208]

200. Raffi ER, Nonacs R, Cohen LS. Safety of psychotropic medications during pregnancy. Clin Perinatol.
2019;46(2):215-234. doi:10.1016/j.clp.2019.02.004 [PubMed 31010557]

201. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs. haloperidol in
delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009;13(3):R75. doi:
10.1186/cc7890. [PubMed 19454032]

202. Remelli F, Bugada M, Matteucci G, et al. An unwanted reaction by the use of Haloperidol in hyperkinetic delirium
[published online ahead of print July 15, 2020]. Aging Clin Exp Res. 2020;10.1007/s40520-020-01649-2.
doi:10.1007/s40520-020-01649-2 [PubMed 32671642]

203. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching
antipsychotics: what is the evidence? Schizophr Res. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.
[PubMed 15949658]

204. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of
antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546.